Timothy C. Barabe Buys 5,000 Shares of Selecta Biosciences, Inc. (SELB) Stock

Selecta Biosciences, Inc. (NASDAQ:SELB) Director Timothy C. Barabe purchased 5,000 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of $9.37 per share, for a total transaction of $46,850.00. Following the purchase, the director now directly owns 4,992 shares in the company, valued at $46,775.04. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Selecta Biosciences, Inc. (NASDAQ:SELB) traded down $0.03 during mid-day trading on Monday, hitting $9.03. 297,600 shares of the stock traded hands, compared to its average volume of 246,767. Selecta Biosciences, Inc. has a 12-month low of $8.70 and a 12-month high of $28.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 9.48 and a current ratio of 9.48.

Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Friday, August 11th. The company reported ($0.85) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.01. The firm had revenue of $0.03 million for the quarter. Selecta Biosciences had a negative net margin of 1,918.59% and a negative return on equity of 100.06%. equities analysts forecast that Selecta Biosciences, Inc. will post -2.25 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Timothy C. Barabe Buys 5,000 Shares of Selecta Biosciences, Inc. (SELB) Stock” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/11/14/timothy-c-barabe-buys-5000-shares-of-selecta-biosciences-inc-selb-stock.html.

SELB has been the topic of several analyst reports. Canaccord Genuity set a $25.00 price target on shares of Selecta Biosciences and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Zacks Investment Research cut shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. ValuEngine cut shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, UBS AG cut shares of Selecta Biosciences from a “buy” rating to a “neutral” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Selecta Biosciences currently has an average rating of “Buy” and a consensus target price of $25.20.

Several hedge funds have recently made changes to their positions in SELB. Nationwide Fund Advisors raised its position in shares of Selecta Biosciences by 224.5% during the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock valued at $131,000 after purchasing an additional 4,561 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Selecta Biosciences during the 1st quarter valued at $211,000. The Manufacturers Life Insurance Company raised its position in shares of Selecta Biosciences by 827.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock valued at $224,000 after purchasing an additional 10,040 shares during the period. Rhumbline Advisers bought a new stake in shares of Selecta Biosciences during the 2nd quarter valued at $239,000. Finally, New York State Common Retirement Fund raised its position in shares of Selecta Biosciences by 184.0% during the 2nd quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock valued at $248,000 after purchasing an additional 8,099 shares during the period. Hedge funds and other institutional investors own 53.03% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply